Formosa Pharmaceuticals
Focus: Formosa Pharmaceuticals is a Taiwan-based public pharmaceutical company specializing in Activus Pure Nanoparticle Technology with a focus on neurology and ophthalmology. The company operates a lean pipeline anchored in late-stage clinical programs and generic/branded oncology assets.
Profile data last refreshed 23h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Formosa Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Formosa Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Formosa Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Post-LOE
Generic microtubule-targeting chemotherapy in post-LOE phase; represents cash-generative but mature revenue base with limited growth trajectory.
Products & Portfolio (1)
Help build intelligence for Formosa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.